Notice of Availability for Exclusive, Non-Exclusive, or Partially-Exclusive Licensing of an Invention Concerning Antibodies With Simultaneous Subsite Specificities to Protein and Lipid Epitopes, 6814 [2013-02097]
Download as PDF
srobinson on DSK4SPTVN1PROD with
6814
Federal Register / Vol. 78, No. 21 / Thursday, January 31, 2013 / Notices
• Testimony from representatives of
the military criminal investigation
organizations.
• Testimony from subject matter
experts on the military justice system.
• Receipt of public comments—3:00
p.m. to 4:00 p.m.
Availability of Materials for the
Meeting: A copy of the agenda for the
February 15, 2013 meeting and the
tasking for the Subcommittee may be
obtained at the meeting or from the
Board’s Staff Director at
StaffDirectorDefenseLegalPolicyBoard@
osd.mil.
Public’s Accessibility to the Meeting:
Pursuant to 5 U.S.C. 552b and 41 CFR
102–3.140 through 102–3.165, and the
availability of space, part of this meeting
is open to the public. Seating is limited
and is on a first-come basis.
Special Accommodations: Individuals
requiring special accommodations to
access the public meeting should
contact the Staff Director at
StaffDirectorDefenseLegalPolicyBoard@
osd.mil at least five (5) business days
prior to the meeting so that appropriate
arrangements can be made.
Procedures for Providing Public
Comments: Pursuant to 41 CFR 102–
3.105(j) and 102–3.140, and section
10(a)(3) of the Federal Advisory
Committee Act of 1972, the public or
interested organizations may submit
written comments to the Board about its
mission and topics pertaining to this
public session. Written comments must
be received by the Designated Federal
Officer at least five (5) business days
prior to the meeting date so that the
comments may be made available to the
Board for their consideration prior to
the meeting. Written comments should
be submitted via email to the address for
the Designated Federal Officer in FOR
FURTHER INFORMATION CONTACT in the
following formats: Adobe Acrobat,
WordPerfect, or Microsoft Word. Please
note that since the Board operates under
the provisions of the Federal Advisory
Committee Act, as amended, all written
comments will be treated as public
documents and will be made available
for public inspection. If members of the
public are interested in making an oral
statement, a written statement must be
submitted as above along with a request
to provide an oral statement. After
reviewing the written comments, the
Chairperson and the Designated Federal
Officer will determine who of the
requesting persons will be able to make
an oral presentation of their issue
during the open portion of this meeting.
Determination of who will be making an
oral presentation is at the sole discretion
of the Committee Chair and the
Designated Federal Officer and will
VerDate Mar<15>2010
17:38 Jan 30, 2013
Jkt 229001
depend on time available and relevance
to the Committee’s activities. Five
minutes will be allotted to persons
desiring to make an oral presentation.
Oral presentations by members of the
public will be permitted from 3:00 p.m.
to 4:00 p.m. in front of the Board. The
number of oral presentations to be made
will depend on the number of requests
received from members of the public.
Committee’s Designated Federal
Officer: The Board’s Designated Federal
Officer is Mr. James Schwenk, Defense
Legal Policy Board, PO Box 3656,
Arlington, VA 22203. Email:
defenselegalpolicyboarddfo@osd.mil.
Phone: (703) 697–9343. For meeting
information please contact Mr. David
Gruber, Defense Legal Policy Board, PO
Box 3656, Arlington, VA 22203. Email:
StaffDirectorDefenseLegalPolicyBoard@
osd.mil. Phone: (703) 696–5449.
Dated: January 25, 2013.
Aaron Siegel,
Alternate OSD Federal Register Liaison
Officer, Department of Defense.
[FR Doc. 2013–02033 Filed 1–30–13; 8:45 am]
BILLING CODE 5001–06–P
Department of the Army
Notice of Availability for Exclusive,
Non-Exclusive, or Partially-Exclusive
Licensing of an Invention Concerning
Antibodies With Simultaneous Subsite
Specificities to Protein and Lipid
Epitopes
Department of the Army, DoD.
Notice.
AGENCY:
Announcement is made of the
availability for licensing of the
invention set forth in U.S. Patent
Application Serial No. 11/525,574,
entitled ‘‘Antibodies with Simultaneous
Subsite Specificities to Protein and
Lipid Epitopes,’’ filed on September 22,
2006. The United States Government as
represented by the Secretary of the
Army has rights to this invention.
Foreign rights may be available.
ADDRESSES: Commander, U.S. Army
Medical Research and Materiel
Command, ATTN: Command Judge
Advocate, MCMR–JA, 504 Scott Street,
Fort Detrick, Frederick, MD 21702–
5012.
SUMMARY:
For
patent issues, Ms. Elizabeth Arwine,
Patent Attorney, (301) 619–7808. For
licensing issues, Dr. Paul Mele, Office of
Research and Technology Applications
(ORTA), (301) 619–6664, both at telefax
(301) 619–5034.
FOR FURTHER INFORMATION CONTACT:
PO 00000
Frm 00012
Fmt 4703
Brenda S. Bowen,
Army Federal Register Liaison Officer.
[FR Doc. 2013–02097 Filed 1–30–13; 8:45 am]
BILLING CODE 3710–08–P
DEPARTMENT OF DEFENSE
Department of the Army; Army Corps
of Engineers
Notice of Intent to Prepare an
Environmental Impact Statement for
the Sacramento-San Joaquin Delta
Islands and Levees Feasibility Study
Department of the Army, U.S.
Army Corps of Engineers; DoD.
ACTION: Notice of intent.
AGENCY:
The action being taken is the
preparation of an environmental impact
statement (EIS) for the Sacramento-San
Joaquin Delta Islands and Levees
Feasibility Study (Delta Study). The EIS
will be prepared in accordance with the
National Environmental Policy Act
(NEPA). The U.S. Army Corps of
Engineers (Corps) will serve as lead
agency for compliance with NEPA. The
Delta Study will evaluate alternatives to
meet the study goals of restoring
sustainable ecosystem functions and
improving flood risk management in the
Delta, Suisun Marsh, and adjacent areas.
DATES: Written comments regarding the
scope of the environmental analysis
should be received at (see ADDRESSES)
by March 15, 2013.
ADDRESSES: Written comments
concerning this study and requests to be
included on the Delta Study mailing list
should be submitted to U.S. Army Corps
of Engineers, Sacramento District,
Public Affairs Office, Attn: Delta Study
Scoping, 1325 J Street, Sacramento, CA
95814.
FOR FURTHER INFORMATION CONTACT: The
U.S. Army Corps of Engineers Public
Affairs Office via telephone at (916)
557–7461, email at spkpao@usace.army.mil, or regular mail at
(see ADDRESSES).
SUPPLEMENTARY INFORMATION:
1. Proposed Action. The Corps is
preparing an EIS to analyze the
environmental impacts associated with
alternatives for restoring sustainable
ecosystem functions and improving
SUMMARY:
DEPARTMENT OF DEFENSE
ACTION:
The
invention relates to a method of making
antibodies that are dual specific to both
(1) amino acid sequences and (2) solid
phase lipid structures. The invention
has relevance to such important subject
matter as making broadly neutralizing
monoclonal antibodies to HIV–1.
SUPPLEMENTARY INFORMATION:
Sfmt 4703
E:\FR\FM\31JAN1.SGM
31JAN1
Agencies
[Federal Register Volume 78, Number 21 (Thursday, January 31, 2013)]
[Notices]
[Page 6814]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2013-02097]
-----------------------------------------------------------------------
DEPARTMENT OF DEFENSE
Department of the Army
Notice of Availability for Exclusive, Non-Exclusive, or
Partially-Exclusive Licensing of an Invention Concerning Antibodies
With Simultaneous Subsite Specificities to Protein and Lipid Epitopes
AGENCY: Department of the Army, DoD.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: Announcement is made of the availability for licensing of the
invention set forth in U.S. Patent Application Serial No. 11/525,574,
entitled ``Antibodies with Simultaneous Subsite Specificities to
Protein and Lipid Epitopes,'' filed on September 22, 2006. The United
States Government as represented by the Secretary of the Army has
rights to this invention. Foreign rights may be available.
ADDRESSES: Commander, U.S. Army Medical Research and Materiel Command,
ATTN: Command Judge Advocate, MCMR-JA, 504 Scott Street, Fort Detrick,
Frederick, MD 21702-5012.
FOR FURTHER INFORMATION CONTACT: For patent issues, Ms. Elizabeth
Arwine, Patent Attorney, (301) 619-7808. For licensing issues, Dr. Paul
Mele, Office of Research and Technology Applications (ORTA), (301) 619-
6664, both at telefax (301) 619-5034.
SUPPLEMENTARY INFORMATION: The invention relates to a method of making
antibodies that are dual specific to both (1) amino acid sequences and
(2) solid phase lipid structures. The invention has relevance to such
important subject matter as making broadly neutralizing monoclonal
antibodies to HIV-1.
Brenda S. Bowen,
Army Federal Register Liaison Officer.
[FR Doc. 2013-02097 Filed 1-30-13; 8:45 am]
BILLING CODE 3710-08-P